Improving Prognosis for Kidney Disorders
Editat de M.M. Avramen Limba Engleză Paperback – 8 dec 2010
Suitable for researchers and clinicians, Dr. Morrell Michael Avram has collected and commented on promising initiatives likely to enter everyday practice in the immediate future. Suitable for renal trainees, experienced kidney doctors, nurses, nutritionists and cardiologists.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 683.93 lei 6-8 săpt. | |
SPRINGER NETHERLANDS – 8 dec 2010 | 683.93 lei 6-8 săpt. | |
Hardback (1) | 691.48 lei 6-8 săpt. | |
SPRINGER NETHERLANDS – 31 oct 2002 | 691.48 lei 6-8 săpt. |
Preț: 683.93 lei
Preț vechi: 719.92 lei
-5% Nou
Puncte Express: 1026
Preț estimativ în valută:
130.90€ • 138.09$ • 109.08£
130.90€ • 138.09$ • 109.08£
Carte tipărită la comandă
Livrare economică 02-16 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789048161645
ISBN-10: 9048161649
Pagini: 156
Ilustrații: XVI, 134 p.
Dimensiuni: 178 x 254 x 8 mm
Greutate: 0.3 kg
Ediția:2002
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9048161649
Pagini: 156
Ilustrații: XVI, 134 p.
Dimensiuni: 178 x 254 x 8 mm
Greutate: 0.3 kg
Ediția:2002
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. How to Achieve Maximal Renoprotection in Non-Diabetic Chronic Renal Disease.- 2. Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa.- 3. Cardiovascular Disease in Patients with Chronic Kidney Disease: The Causes and Effects.- 4. Metabolic Pathogenesis of Cardio-Renal Disease.- 5. Oxidative Stress and Inflammation in Hemodialysis Patients.- 6. Prognostic Value of Enrollment Parathyroid Hormone in Hemodialysis and Peritoneal Dialysis Patients for Survival. A 14 years Follow-up.- 7. Prealbumin as an Important Predictor for Survival and Nutritional Status in Hemodialysis and Peritoneal Dialysis Patients.- 8. How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria.- 9. Hypoalbuminemia in the Patient with Renal Disease: Its Causes and Consequences.- 10. Kidney Disease and Mechanisms that Cause Loss of Muscle Mass.- 11. Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy.- 12. Effects of Erythropoietin (EPO) and Aminoguanidine (AG) on Deformability (df) in Diabetic Azotemic and Uremic Patients.- 13. Characterization of the PKD1 Gene Product, Polycystin-1.- 14. Nutrition and Blood Pressure.- 15. How to Minimize Bone Disease in Renal Failure.